Prilosec

Prilosec is a pharmaceutical brand for omeprazole, a proton-pump inhibitor that suppresses gastric-acid production. Omeprazole is used in the treatment of acid-related disorders including gastroesophageal reflux disease, erosive esophagitis, peptic ulcers, and hypersecretory conditions such as Zollinger–Ellison syndrome. It is also used, in combination with antibiotics, in treatment regimens for some Helicobacter pylori infections. The product was developed by Astra, the Swedish pharmaceutical company that later became part of AstraZeneca. Omeprazole was first introduced internationally under the Losec name and was marketed in the United States as Prilosec. The brand became one of the best-known proton-pump inhibitors and helped establish long-term acid suppression as a standard treatment approach for reflux and ulcer disease. Prilosec has been sold in prescription and over-the-counter forms. Prescription formulations were used for physician-directed treatment of diagnosed acid-related conditions, while Prilosec OTC was introduced in the United States for frequent heartburn in adults. The over-the-counter product contains omeprazole delayed-release tablets and is intended for short courses according to its labeling rather than immediate relief of occasional heartburn. Its delayed-release design protects the active ingredient from degradation in the stomach and allows release in the small intestine. The brand is associated with AstraZeneca as the originator and owner of the underlying branded product, although commercialization arrangements for the over-the-counter version have involved other consumer-health companies. Omeprazole is now also available from numerous generic manufacturers, so Prilosec competes principally through brand recognition, distribution, packaging, and consumer familiarity rather than exclusivity over the active ingredient. As with other proton-pump inhibitors, product labeling and medical guidance address potential risks associated with inappropriate, prolonged, or interacting use. These include possible nutrient deficiencies, drug interactions, infection-related risks, and other adverse effects. The brand therefore occupies both a consumer self-care position through Prilosec OTC and a prescription-gastroenterology position through its historical prescription use.

Prilosec's history is rooted in the development of omeprazole by Astra, the Swedish pharmaceutical company that later combined with Zeneca to form AstraZeneca. Omeprazole belongs to the proton-pump inhibitor class, which works by inhibiting the gastric proton pump responsible for the final stage of stomach-acid secretion. This mechanism made it more potent and sustained than earlier acid-reducing medicines and gave it an important role in the treatment of reflux disease, peptic-ulcer disease, and other acid-related disorders. The medicine was introduced internationally under the Losec brand. In the United States, Astra marketed the product as Prilosec. The prescription brand became widely associated with treatment of gastroesophageal reflux disease and erosive esophagitis, as well as ulcer-related conditions and certain hypersecretory disorders. It was also used as one component of combination therapy directed at Helicobacter pylori, the bacterium linked to many peptic ulcers. Astra and Zeneca merged in 1999, creating AstraZeneca and placing the Prilosec brand within the new group's pharmaceutical portfolio. During the prescription period, omeprazole became one of the most commercially important medicines in the gastrointestinal market. Its success reflected both the clinical adoption of proton-pump inhibition and the broad prevalence of reflux and ulcer conditions. A major later transition was the movement of omeprazole into the U.S. over-the-counter market. In 2003, the FDA approved Prilosec OTC for adults with frequent heartburn, subject to consumer labeling and course limitations. This changed the brand's role from a primarily physician-prescribed medicine into a recognizable self-care product. The OTC product uses delayed-release tablets and is not designed to provide instant relief from an isolated episode of heartburn. As patent and regulatory exclusivity ended, generic omeprazole became broadly available. Prilosec consequently continued as a branded product while competing with lower-priced generic versions and with other proton-pump-inhibitor brands such as Nexium, Prevacid, and Protonix. The brand's continuing significance comes from its historical role in popularizing omeprazole, its consumer recognition, and the continuing use of the active ingredient in clinical practice. The modern product context also includes increased attention to the appropriate duration of proton-pump-inhibitor therapy. U.S. labeling and public-health information warn consumers to follow directions, consider medical evaluation when symptoms persist or recur, and account for contraindications and drug interactions. These safety considerations are part of the brand's current positioning as a regulated medicine rather than an unrestricted general wellness product.

• 2003

  Prilosec OTC approved

  [1]FDA approves Prilosec OTC for frequent heartburnfda.gov

  The FDA approved Prilosec OTC for the treatment of frequent heartburn in adults, making omeprazole available without a prescription in the United States.

• 1999

  AstraZeneca formed

  [3]AstraZeneca company historyastrazeneca.com

  Astra merged with Zeneca to form AstraZeneca, which became the corporate home of the Prilosec brand.

• 1989

  U.S. approval of Prilosec

  [2]Prilosec prescribing informationaccessdata.fda.gov

  The U.S. Food and Drug Administration approved prescription Prilosec, the U.S. brand of omeprazole.

• 1988

  International introduction of omeprazole

  [4]Omeprazoleen.wikipedia.org

  Omeprazole was introduced internationally by Astra under the Losec brand, establishing the product that would later be marketed as Prilosec in the United States.

An established acid-reduction brand spanning prescription gastroenterology and over-the-counter heartburn self-care.

• Prescription proton-pump inhibitor · 1989

  Prilosec prescription

  Prescription Prilosec contains omeprazole in a delayed-release formulation. It has been used under medical supervision for gastroesophageal reflux disease, erosive esophagitis, peptic-ulcer conditions, hypersecretory disorders, and as part of selected Helicobacter pylori eradication regimens. Prescription use is determined by the diagnosis, dose, duration, and other medicines involved.

• Over-the-counter heartburn medicine · 2003

  Prilosec OTC

  Prilosec OTC is an over-the-counter delayed-release omeprazole product approved in the United States for adults with frequent heartburn. Its labeling describes a course of treatment for recurring symptoms and emphasizes that it is not intended for immediate relief. Consumers are directed to seek medical advice for persistent, recurrent, or concerning symptoms.

• 2003

  Move from prescription to over-the-counter distributionProduct launch

  Background

  AstraZeneca sought regulatory approval to make omeprazole available directly to consumers for frequent heartburn in the United States.

  Action taken

  The FDA approved Prilosec OTC under consumer labeling that specified the intended population, course of use, and circumstances requiring medical advice.

  Aftermath

  The decision expanded the brand into the consumer-health market while generic omeprazole and competing acid-reduction brands remained available.

  Source

1. 1FDA approves Prilosec OTC for frequent heartburnfda.gov
2. 2Prilosec prescribing informationaccessdata.fda.gov
3. 3AstraZeneca company historyastrazeneca.com
4. 4Omeprazoleen.wikipedia.org